Thursday, May 15, 2014
Publication and contact
Direct in vivo
reprogramming of pancreatic acinar cells into d-like and a-like
Direct in vivo
reprogramming of pancreatic acinar cells into d- and a-like
pancreatic islet cells could be used to generate pancreatic islets to treat
diseases such as type 1 diabetes. In mice, intrapancreatic injection of an
adenoviral vector encoding neurogenin
converted acinar cells into d-like pancreatic
islet cells. In mice, intrapancreatic injection of adenoviral vectors
encoding Ngn3 and v-maf
musculoaponeurotic fibrosarcoma oncogene homolog A (Mafa;
converted acinar cells into a-like pancreatic
islet cells. Next steps include creating islets that contain the full
repertoire of acinar tissue-derived endocrine cells.
Published online May 15, 2014
Patented; available for
Li, W. et al. eLife;
published online April 8, 2014;
Contact: Qiao Zhou, Harvard University, Cambridge, Mass.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]